{"document_type": "article", "byline": {"person": [{"role": "reported", "firstname": "Robert", "organization": "", "rank": 1, "lastname": "CYRAN"}], "original": "By ROBERT CYRAN"}, "news_desk": "Business", "slideshow_credits": null, "abstract": null, "multimedia": [{"type": "image", "url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbWide.jpg", "legacy": {"wide": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbWide.jpg", "wideheight": "126", "widewidth": "190"}, "width": 190, "subtype": "wide", "height": 126}, {"type": "image", "url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg", "legacy": {"xlarge": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-articleLarge.jpg", "xlargewidth": "600", "xlargeheight": "400"}, "width": 600, "subtype": "xlarge", "height": 400}, {"type": "image", "url": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg", "legacy": {"thumbnail": "images/2016/04/07/business/07DB-PFIZERsub/07DB-PFIZERsub-thumbStandard.jpg", "thumbnailwidth": "75", "thumbnailheight": "75"}, "width": 75, "subtype": "thumbnail", "height": 75}], "headline": {"kicker": "Breakingviews", "content_kicker": "Breakingviews", "main": "Pfizer Remains Whole, but the Option to Split Could Return"}, "print_page": null, "keywords": [{"value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "2", "name": "subject"}, {"value": "Pfizer Inc", "is_major": "N", "rank": "3", "name": "organizations"}, {"value": "Read, Ian C", "is_major": "N", "rank": "4", "name": "persons"}], "snippet": "Wall Street has given Pfizer the benefit of the doubt, but investors do not universally love the decision not to break up....", "source": "The New York Times", "lead_paragraph": "Wall Street has given Pfizer the benefit of the doubt, but investors do not universally love the decision not to break up.", "word_count": "396", "pub_date": "2016-09-27T04:00:00+0000", "subsection_name": "DealBook", "blog": [], "type_of_material": "News", "section_name": "Business Day", "web_url": "http://www.nytimes.com/2016/09/27/business/dealbook/pfizer-remains-whole-but-the-option-to-split-could-return.html", "_id": "57e95e8895d0e021d7988700"}